Casa bronstein meier ii

Impact of anti-CD20 monoclonal antibodies on serologic response to

Por um escritor misterioso

Last updated 15 março 2025

Impact of anti-CD20 monoclonal antibodies on serologic response to

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies - ScienceDirect

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response - ScienceDirect

Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Frontiers IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis - ScienceDirect

Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

JCI Insight - Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies - Biology of Blood and Marrow Transplantation

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Recomendado para você